Cellectar Financial Statements From 2010 to 2025

CLRB Stock  USD 5.59  0.39  7.50%   
Cellectar Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cellectar Biosciences' valuation are provided below:
Market Capitalization
14.9 M
Earnings Share
(18.90)
We have found one hundred twenty available fundamental signals for Cellectar Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Cellectar Biosciences prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of July 23, 2025, Market Cap is expected to decline to about 10.4 M. The current year's Enterprise Value is expected to grow to about (11.3 M)

Cellectar Biosciences Total Revenue

0.0

Check Cellectar Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cellectar Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 289 K, Interest Expense of 363.4 K or Total Revenue of 0.0, as well as many indicators such as Dividend Yield of 0.46, Ptb Ratio of 0.73 or Days Sales Outstanding of 741. Cellectar financial statements analysis is a perfect complement when working with Cellectar Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Cellectar Stock
Check out the analysis of Cellectar Biosciences Correlation against competitors.
For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.

Cellectar Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets15.8 M25.5 M17.3 M
Slightly volatile
Short and Long Term Debt Total552.5 K494 K483.9 K
Slightly volatile
Other Current Liabilities9.1 M8.7 MM
Slightly volatile
Total Current LiabilitiesM9.4 M4.2 M
Slightly volatile
Accounts Payable580.5 K611 K1.2 M
Slightly volatile
Cash13.3 M23.3 M14.4 M
Slightly volatile
Non Current Assets Total1.8 M1.2 M2.3 M
Slightly volatile
Non Currrent Assets Other25.5 K26.8 K192.9 K
Pretty Stable
Cash And Short Term Investments13.3 M23.3 M14.4 M
Slightly volatile
Net Receivables10.1 K11.3 K12.3 K
Slightly volatile
Common Stock Shares Outstanding39 M37.1 M6.5 M
Slightly volatile
Liabilities And Stockholders Equity15.8 M25.5 M17.3 M
Slightly volatile
Non Current Liabilities Total1.5 M1.8 M505 K
Slightly volatile
Other Current Assets851.1 K961.7 K794.7 K
Slightly volatile
Other Stockholder Equity274.2 M261.1 M123.6 M
Slightly volatile
Total Liabilities11.7 M11.2 MM
Slightly volatile
Total Current Assets14 M24.3 M15 M
Slightly volatile
Short Term Debt80.2 K84.4 K214.6 K
Slightly volatile
Common Stock400461261
Pretty Stable
Property Plant And Equipment Net1.1 M1.2 M1.3 M
Slightly volatile
Common Stock Total Equity449409304
Pretty Stable
Property Plant And Equipment Gross1.2 M2.2 M1.4 M
Pretty Stable
Other Liabilities155.6 K196.6 K156.9 K
Slightly volatile
Short Term Investments88.4 K49.5 K88 K
Slightly volatile
Property Plant Equipment1.2 M881.1 K1.4 M
Slightly volatile
Intangible Assets1.8 M1.9 M1.7 M
Slightly volatile
Long Term Debt Total1.9 KK141.3 K
Slightly volatile
Capital Surpluse103.4 M185.8 M105.2 M
Slightly volatile
Capital Lease Obligations293.6 K494 K204.6 K
Slightly volatile
Long Term Investments64.1 K67.5 K335.9 K
Slightly volatile
Capital Stock495.2 K521.2 K3.4 M
Very volatile

Cellectar Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization289 K291.7 K355.8 K
Pretty Stable
Interest Expense363.4 K346.1 K157.9 K
Pretty Stable
Other Operating Expenses47 M44.8 M18.3 M
Slightly volatile
Research Development27.4 M26.1 M11.6 M
Slightly volatile
Total Operating Expenses54.4 M51.8 M19.2 M
Slightly volatile
Selling General Administrative26.9 M25.6 M7.7 M
Slightly volatile
Non RecurringM1.9 M1.4 M
Slightly volatile
Non Operating Income Net Other158.4 K166.8 KM
Slightly volatile
Interest Income681.6 K1.2 M1.6 M
Slightly volatile
Net Interest Income1.3 M1.2 M199.2 K
Slightly volatile
Reconciled Depreciation265.3 K291.7 K858.8 K
Slightly volatile
Selling And Marketing Expenses625.7 K945.2 K266.5 K
Slightly volatile

Cellectar Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation282.5 K291.7 K347.7 K
Pretty Stable
Capital Expenditures147.1 K104.2 K176.6 K
Slightly volatile
Total Cash From Financing Activities64.5 M61.4 M19.5 M
Slightly volatile
End Period Cash Flow13.3 M23.3 M14.4 M
Slightly volatile
Begin Period Cash Flow12.6 M9.6 M12.9 M
Slightly volatile
Stock Based Compensation4.5 M4.3 M1.1 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Dividend Yield0.460.440.2728
Slightly volatile
Days Sales Outstanding741833908
Slightly volatile
Average Payables1.4 M1.4 M894.5 K
Slightly volatile
Capex To Depreciation0.340.35730.8985
Slightly volatile
Payables Turnover0.03740.0394178
Slightly volatile
Sales General And Administrative To Revenue70.4867.1270.2826
Slightly volatile
Cash Per Share0.60.6359814
Slightly volatile
Days Payables Outstanding11.6 K12.3 K21.3 K
Slightly volatile
Income Quality0.541.06730.9069
Very volatile
Intangibles To Total Assets0.180.150.1503
Pretty Stable
Current Ratio2.452.58325.2684
Very volatile
Receivables Turnover0.310.350.3863
Slightly volatile
Capex Per Share0.00270.002813.7216
Slightly volatile
Interest Debt Per Share0.01280.013530.9 K
Slightly volatile
Debt To Assets0.01840.01941.188
Slightly volatile
Graham Number41 K46.2 K50.3 K
Slightly volatile
Operating Cycle741833908
Slightly volatile
Days Of Payables Outstanding11.6 K12.3 K21.3 K
Slightly volatile
Ebt Per Ebit1.230.85970.9633
Very volatile
Long Term Debt To Capitalization0.08290.05740.0601
Very volatile
Quick Ratio2.452.58325.2684
Very volatile
Net Income Per E B T0.671.00150.965
Slightly volatile
Cash Ratio2.362.48075.0244
Very volatile
Days Of Sales Outstanding741833908
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.811.00220.9997
Slightly volatile
Debt Ratio0.01840.01941.188
Slightly volatile
Gross Profit Margin0.390.440.4793
Slightly volatile

Cellectar Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap10.4 M11 M14.5 M
Pretty Stable

Cellectar Fundamental Market Drivers

Cash And Short Term Investments23.3 M

Cellectar Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cellectar Biosciences Financial Statements

Cellectar Biosciences stakeholders use historical fundamental indicators, such as Cellectar Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Cellectar Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cellectar Biosciences' assets and liabilities are reflected in the revenues and expenses on Cellectar Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cellectar Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.8 M2.9 M
Cost Of Revenue221.2 K263.9 K
Stock Based Compensation To Revenue(94.87)(90.13)
Sales General And Administrative To Revenue 67.12  70.48 
Research And Ddevelopement To Revenue(376.27)(357.45)
Capex To Revenue(12.38)(11.76)
Revenue Per Share(10.57)(10.04)
Ebit Per Revenue 575.81  604.60 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:
Check out the analysis of Cellectar Biosciences Correlation against competitors.
For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(18.90)
Return On Assets
(0.98)
Return On Equity
(2.09)
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.